Using basic fibroblast growth factor nanoliposome combined with ultrasound-introduced technology to early intervene the diabetic cardiomyopathy

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 675-686

  Zhao, Ying Zheng ^a   Zhang, Ming ^a   Tian, Xin Qiao ^b   Zheng, Lei ^a   Lu, Cui Tao ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

BFGF loaded liposome; Diabetic cardiomyopathy; Prevention; Targeted delivery

Indexed keywords

CASPASE 3; COLLAGEN; FIBROBLAST GROWTH FACTOR 2; NANOCARRIER; NANOLIPOSOME; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; STREPTOZOCIN; UNCLASSIFIED DRUG; LIPOSOME; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIAC MYOCYTE APOPTOSIS INDEX; CARDIOVASCULAR PARAMETERS; CELL ULTRASTRUCTURE; COLLAGEN VOLUME FRACTION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; EARLY INTERVENTION; GENE DELIVERY SYSTEM; HEART FUNCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; HEMODYNAMICS; IMMUNOHISTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; M MODE ECHOCARDIOGRAPHY; METABOLIC DISORDER; MICROVASCULAR DENSITY; MYOCARDIAL CAPILLARY DENSITY; NONHUMAN; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TUNEL ASSAY; ULTRASOUND TARGETED MICROBUBBLE DESTRUCTION; WESTERN BLOTTING; ANIMAL; CARDIAC MUSCLE; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ENZYME IMMUNOASSAY; HEART LEFT VENTRICLE FUNCTION; HIGH-ENERGY SHOCK WAVE; METABOLISM; MICROBUBBLE; MULTIMODALITY CANCER THERAPY; PREVENTION AND CONTROL; ULTRASOUND;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; FIBROBLAST GROWTH FACTOR 2; HIGH-ENERGY SHOCK WAVES; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; LIPOSOMES; MICROBUBBLES; MYOCARDIUM; NANOPARTICLES; RATS; ULTRASONICS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84975747920     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S99376     Document Type: Article

References (31)

1. Goyal BR, Mehta AA. Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfuntion. Hum Exp Toxicol. 2013;32:571-590.
2. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013;18: 149-166.
3. Delucchi F, Berni R, Frati C, et al. Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS One. 2012;7:e39836.
4. Fowlkes V, Clark J, Fix C, et al. Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life Sci. 2013;92: 669-676.
5. Zhang H, Zhang Y, Li Z, et al. Left ventricular radial systolic dysfunction in diabetic patients assessed by myocardial acceleration derived from velocity vector imaging. J Ultrasound Med. 2012;31:1179-1186.
6. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442-447.
7. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A. 1986;83:7297-7301.
8. Desire L, Courtois Y, Jeanny JC. Endogenous and exogenous fibroblast growth factor 2 support survival of chick retinal neurons by control of neuronal neuronal bcl-x(L) and bcl-2 expression through a fibroblast berowth factor receptor 1- and ERK-dependent pathway. J Neurochem. 2000;75:151-163.
9. Wang Y, He H, Zigler JS Jr, et al. bFGF suppresses serum-deprivation-induced apoptosis in a human lens epithelial cell line. Exp Cell Res. 1999;249:123-130.
10. Duvs.hani-Eshet M, Machluf M. Therapeutic ultrasound optimization for gene delivery: a key factor achieving nuclear DNA localization. J Control Release. 2005;108:513-528.
11. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. Ultrasound-mediated transfection of mammalian cells. Hum Gene Ther. 1996;7:1339-1346.
12. Chappell JC, Song J, Burke CW, Klibanov AL, Price RJ. Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis. Small. 2008;4:1769-1777.
13. Rapoport N, Kennedy AM, Shea JE, Scaife CL, Nam KH. Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging. Mol Pharm. 2010;7:22-31.
14. Tian JL, Zhao YZ, Jin Z, et al. Synthesis and characterization of Poloxamer 188-grafted heparin copolymer. Drug Dev Ind Pharm. 2010;36:832-838.
15. Zhao YZ, Tian XQ, Zhang M, et al. Functional and pathological improvements of the hearts in diabetes model by the combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted microbubble destruction. J Control Release. 2014;186C:22-31.
16. Zhao YZ, Tian XQ, Zhang M, et al. Functional and pathological improvements of the hearts in diabetes model by the combined therapy of bFGF-loaded nanoparticles with ultrasound-targeted microbubble destruction. J Control Release. 2014;186:22-31.
17. Wang J, Song Y, Elsherif L, et al. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation. 2006;113:544-554.
18. Khurana R, Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med. 2003;13:116-122.
19. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2:REVIEWS3005.
20. Fujii H, Li SH, Wu J, et al. Repeated and targeted transfer of angiogenic plasmids into the infarcted rat heart via ultrasound targeted microbubble destruction enhances cardiac repair. Eur Heart J. 2011;32:2075-2084.
21. Zhao YZ, Luo YK, Lu CT, et al. Phospholipids-based microbubbles sonoporation pore size and reseal of cell membrane cultured in vitro. J Drug Target. 2008;16:18-25.
22. Nunes S, Soares E, Fernandes J, et al. Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol. 2013;12:44.
23. Meloni M, Descamps B, Caporali A, et al. Nerve growth factor gene therapy using adeno-associated viral vectors prevents cardiomyopathy in type 1 diabetic mice. Diabetes. 2012;61:229-240.
24. Armstrong SC. Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;61:427-436.
25. Ananthakrishnan R, Moe GW, Goldenthal MJ, Marin-Garcia J. Akt signaling pathway in pacing-induced heart failure. Mol Cell Biochem. 2005;268:103-110.
26. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905-2927.
27. Linseman DA, Butts BD, Precht TA, et al. Glycogen synthase kinase-3beta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. J Neurosci. 2004;24:9993-10002.
28. Factor SM, Minase T, Sonnenblick EH. Clinical and morphological features of human hypertensive-diabetic cardiomyopathy. Am Heart J. 1980;99:446-458.
29. Kawaguchi M, Techigawara M, Ishihata T, et al. A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Vessels. 1997;12:267-274.
30. Yarom R, Zirkin H, Stammler G, Rose AG. Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material. J Pathol. 1992;166:265-270.
31. Yamamoto N, Kohmoto T, Roethy W, et al. Histologic evidence that basic fibroblast growth factor enhances the angiogenic effects of transmyocardial laser revascularization. Basic Res Cardiol. 2000;95:55-63.